PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA. · 2014
Read PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. by Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4187324.txt.
Description
Brian D. Lehmann, Melinda E. Sanders, and ten co-authors tested a drug pairing for a hard breast cancer subtype in Breast Cancer Research in 2014. Triple negative breast cancers lack the usual drug targets, but one subgroup carries the androgen receptor. Those tumours often carry mutations in the PIK3CA gene, which switches on a growth pathway.
The team found activating PIK3CA mutations in 40 percent of androgen receptor positive cases, against 4 percent of negative ones. In cell and mouse tumour models, blocking the PI3K pathway slowed growth, and blocking the androgen receptor at the same time added to the effect. The pairing of bicalutamide with either of two PI3K blockers worked better than each drug alone. The results support testing the combination in patients with this subtype.
Catalog record
| CREATOR | Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |